CMS为ZEVASKYN分配了永久帐单代号,这是一种罕见皮肤疾病的基因疗法,于2026年1月1日生效。 CMS assigned a permanent billing code to ZEVASKYN, a gene therapy for a rare skin disease, effective Jan. 1, 2026.

美国医疗保险和医疗补助服务中心已将永久的HCPCS J-代码J3389分配给ZEVASKYN (prademagene zamikeracel),这是一种治疗衰退性皮溶解的基因疗法,自2026年1月1日起生效. The Centers for Medicare and Medicaid Services has assigned a permanent HCPCS J-code, J3389, to ZEVASKYN (prademagene zamikeracel), a gene therapy for recessive dystrophic epidermolysis bullosa, effective January 1, 2026. 该守则将统一治疗的计费和报销,治疗使用病人自己改良的皮肤细胞促进伤口愈合。 The code will standardize billing and reimbursement for the treatment, which uses a patient’s own modified skin cells to promote wound healing. 治疗是RDEB的第一个细胞薄基基因疗法,具有过敏反应、潜在的长期癌症风险和感染传播等风险。 The therapy, the first cell sheet-based gene therapy for RDEB, carries risks including allergic reactions, potential long-term cancer risk, and infection transmission. 常见副作用包括疼痛和痒。 Common side effects include pain and itching. 这种疗法是在克利夫兰根据CGMP标准制造的。 The therapy is manufactured in Cleveland under cGMP standards.